BioPharma Dive December 2, 2024
At the center of a new licensing deal is an experimental medicine currently being tested in a roughly 250-person study that should produce results next year.
Novartis could pay close to $3 billion for brain drugs developed by PTC Therapeutics, per a deal announced Monday.
At the center of the deal is an experimental medicine, PTC518, which is currently being tested as a potential treatment for Huntington’s disease in a roughly 250-person clinical trial. The main portion of that study should complete early next year. But ahead of those results, PTC has entered into an exclusive licensing agreement that gives Novartis rights to the medicine as well as related molecules.
The deal is set to close before the end of...
Today's Sponsors
Today's Sponsor